News

Caraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease
CAMBRIDGE, MA –November 18, 2020 – Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This latest grant builds on Caraway’s drug discovery research focused on the role of lysosomal function and autophagy in neurodegenerative and rare diseases to further investigate the […] » Full Story
Caraway Therapeutics to Present at Two Upcoming Virtual Conferences in November 2020
CAMBRIDGE, MA –November 10, 2020 – Caraway Therapeutics today announced that the Company is scheduled to present at two upcoming virtual conferences during November, 2020. Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 8:40am ET. Caraway’s President and Chief Scientific Officer, Magdalene Moran, […] » Full Story
Caraway Therapeutics Expands Leadership Team With Appointment of Martin D. Williams as Chief Executive Officer and Cristina Csimma, PharmD, MHP, as Chair of the Board of Directors
Caraway Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced it has appointed Martin D. Williams as Chief Executive Officer. » Full Story
Rheostat Therapeutics Announces Rebrand to Caraway Therapeutics and New Kendall Square Office
Rheostat Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced the company has changed its name to Caraway Therapeutics. » Full Story
Rheostat Therapeutics Announces $23 Million Series A Financing To Develop Potential Treatments for Neurodegenerative Diseases
Rheostat Therapeutics, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, today announced the close of a Series A financing round totaling $23 million. » Full Story